Načítá se...
Patented small molecule inhibitors in the ubiquitin proteasome system
Deregulation of the ubiquitin proteasome system (UPS) has been implicated in the pathogenesis of many human diseases, including cancer and neurodegenerative disorders. The recent approval of the proteasome inhibitor Velcade(®) (bortezomib) for the treatment of multiple myeloma and mantle cell lympho...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2007
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2106365/ https://ncbi.nlm.nih.gov/pubmed/18047738 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2091-8-S1-S14 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|